Anxiety Disorders Review

Overview of Anxiety and Fear

  • Anxiety is defined as a future-oriented emotional state. It is primarily characterized by:

    • Excessive worry

    • Apprehension

    • Anticipation of a potential threat

    • Physiologic arousal

  • Distinguishing Normal Anxiety vs Anxiety Disorder:

    • Normal Anxiety: a temporary emotional and psychologic response to stress that helps us prepares us for challenges or danger

    • Anxiety Disorder: anxiety that is excessive, persistent, out of proportion to the situation and causes functional impairment that significantly interferes with daily activities, relationships, and overall quality of life.


  • Core cognitive questions associated with anxiety include "What if I fail?", "What if something bad happens?", and "What if this symptom means something serious?"

  • Distinguishing Fear vs. Anxiety:

    • Fear: A response to an immediate threat occurring in the present (NOW\text{NOW}).

    • Anxiety: Recurrent anticipation of a future threat (WHAT IF?\text{WHAT IF?}).

  • Assessing Severity: Persistent worry for months that interferes with sleep and work is a much stronger indicator of an anxiety disorder than brief worry (e.g., after lab results) or situational nervousness (e.g., job interviews or public speaking).

Epidemiology of Anxiety Disorders

  • Anxiety disorders are very common psychiatric conditions, frequently underdiagnosed and often managed in primary care.

  • Lifetime Prevalence: Approximately 30%30\% for any type of anxiety disorder.

  • Gender Distribution: Women are affected more than men at a ratio of approximately 2:12:1.

  • Specific Prevalence Data:

    • Specific Phobia: Approximately 12%12\%

    • Social Anxiety Disorder: Approximately 7 to 12%7 \text{ to } 12\%

    • Generalized Anxiety Disorder (GAD): Approximately 6%6\%

    • Panic Disorder: Approximately 4 to 5%4 \text{ to } 5\%

Etiology: Biological, Psychological, and Environmental Factors

  • Biological Factors:

    • Genetics: Increase risk significant; Twin and Family studies suggest moderate heritability.

    • Family History: Increased risk if there is a family history of anxiety disorders, depression, or substance use disorders.

    • Neurotransmitters: Dysregulation of neurotransmitters such as serotonin, norepinephrine, and gamma-aminobutyric acid (GABA) may contribute to the development of anxiety disorders.

      Neurotransmitter

      Role in Anxiety

      GABA

      Inhibitory neurotransmitter that reduces neuronal excitability; decreased GABA activity is linked to increased anxiety.

      Serotonin

      Influences mood and anxiety levels; SSRIs boost serotonin levels to alleviate anxiety symptoms.

      Norepinephrine

      Associated with the body's stress response; high levels can increase anxiety.

      Dopamine

      Plays a role in reward and motivation; imbalance may contribute to anxiety disorders.

      Cortisol

      The body's primary stress hormone; elevated levels can exacerbate anxiety symptoms.

      Glutamate

      Major excitatory neurotransmitter; dysregulation may be involved in anxiety pathophysiology.

  • Key Brain Regions and Pathophysiology:

    • Amygdala: The threat detection and fear center.

    • Prefrontal Cortex: Responsible for emotional regulation.

    • Hippocampus: Involved in memory and context.

    • Conceptualization: An overactive alarm system paired with under-regulation.

  • Psychological Contributors:

    • Cognitive Distortions: Catastrophizing and overestimating danger.

    • Behavioral Conditioning: Learned fear responses.

    • Personality Traits: High neuroticism and perfectionism.

  • Environmental Risk Factors:

    • Chronic stress

    • Adverse Childhood Experiences (ACES)

    • Trauma and family instability

    • Chronic illness and substance use

    • Major life transitions

Clinical Evaluation and Physical Exam

  • Anxiety is a clinical diagnosis; there are no specific labs or imaging for the disorders themselves.

  • Physical Exam Findings (In-Office):

    • Diaphoresis (sweating)

    • Cool, clammy hands

    • Restless or agitated state

    • Tachycardia (elevated heart rate)

    • Hyperventilation

    • Emotional: excessive worry, fear, irritability

    • Cognitive: rumination, poor concentration, racing thoughts

  • Telehealth Observations:

    • Avoidant behavior or distractibility

    • Restlessness or shaking the camera

    • Smoking on camera

    • Irritability

  • Patient Education for Vitals: Teach the patient how to obtain a radial or carotid pulse; utilize digital health devices.

  • Mental Status Exam (MSE):

    • Alert and Oriented: ×4\times 4

    • Mood: Normal or depressed

    • Affect: Normal

    • Behaviors: Averted gaze, restlessness, fidgeting, skin picking, or bouncing legs.

    • Cognition: Insight and judgment usually remain intact.

    • Risk Assessment: Suicidal ideation is possible and must be assessed.

  • Diagnostic Rule-outs (Labs/Testing):

    • TSH,T4TSH, T4 levels: To rule out hyperthyroidism (The "Biggest One").

    • PTH/CalciumPTH / \text{Calcium} levels: To rule out hyperparathyroidism.

    • Holter monitor or EKG: To rule out cardiac etiologies (e.g., arrhythmias).

    • Urine drug screen: To rule out substance-induced anxiety.

Generalized Anxiety Disorder (GAD)

  • DSM-5 Criteria:

    • A. Excessive anxiety and worry occurring more days than not for at least 6 months6 \text{ months} .

    • B. Difficulty controlling the worry.

    • C. Three or more associated symptoms: Restlessness, being easily fatigued, concentration difficulty, irritability, muscle tension, and sleep disturbance.

    • D. Significant distress or impairment in social/occupational functioning.

    • E. Not attributable to substances or medical conditions (e.g., hyperthyroidism).

    • F. Not better explained by another mental disorder.

  • Screening: The USPSTF recommends annual screening for all adults aged 18 to 6518 \text{ to } 65. The standard tool is the GAD-7 scale.

    • GAD-7 Scoring:

      • 5 to 95 \text{ to } 9: Mild anxiety

      • 10 to 1410 \text{ to } 14: Moderate anxiety

      • 15 to 2115 \text{ to } 21: Severe anxiety

  • Comorbidities: Anxiety rarely travels alone. Common co-occurring conditions include:

    • Major Depressive Disorder (Most common)

    • Substance Use Disorder (Alcohol, cannabis, nicotine, etc.)

    • Insomnia/Sleep Disorders

    • ADHD (Overlap in restlessness and inattention)

    • PTSD and OCD

    • Chronic Pain (Fibromyalgia, migraines; anxiety amplifies pain)

    • GI Medical Conditions (IBS, GERD)

  • Differential Diagnoses: THINC MED

  • Treatment:

    • First-line: SSRIs or SNRIs + Psychotherapy (Cognitive Behavioral Therapy - CBT).

    • Anxiolytics: Buspirone (BusparBuspar), Hydroxyzine (VistarilVistaril) PRN, or short-term Benzodiazepines.

Specific Anxiety Disorders and Their Treatment

  • Social Anxiety Disorder:

    • Characterized by intense, persistent fear of being watched or judged by others.

    • Typically lasts for 6 months or more

    • General Treatment: First-line includes SSRI/SNRI and CBT.

    • Performance- Only Social Anxiety Disorder (e.g., Test Anxiety): CBT and Beta-blockers (propranolol\text{propranolol}).

  • Panic Disorder:

    • Median onset: 20 to 24 years old20 \text{ to } 24 \text{ years old}. Prevalence: 2 to 3%2 \text{ to } 3\% of U.S. adults.

    • High rate of suicide and suicidal ideation.

    • Diagnosis requires at least one of the attacks has been followed by one month or more of one or both of the following:

      • Persistent concern or worry about additional attacks or their consequences

      • Maladaptive change in behavior (e.g., avoidance of certain places)

      • 4 panic attack symptoms include palpitations, sweating, trembling or shaking, and feelings of choking. Additional symptoms may include sensations of shortness of breath, chest pain, nausea, dizziness, or fear of losing control, all of which can significantly impact an individual's daily functioning and overall quality of life.

    • Treatment: CBT (preferred), SSRI/SNRI, Benzos PRN.

  • Agoraphobia:

    • Fear or anxiety about two or more of the following 5 situations:

      • Public Transportation

      • Open Spaces

      • Enclosed Spaces

      • Standing in Line/Crowds

      • Being Outside of the House Alone

    • Fear of situations where escape might be difficult or help might not be available

    • The fear is out of proportion to the actual danger or threat posed by the situation, often leading to significant distress and avoidance behaviors that can impact daily functioning.

    • Lasting typically 6 months6 \text{ months} or more.

    • Treatment: CBT, Exposure and Response Prevention (ERP) Therapy, SSRI/SNRI.

  • Separation Anxiety Disorder:

    • Developmentally inappropriate fear of separation from attachment figures. Displays three of the following:

      • Excessive stress when anticipating or experiencing separation

      • Persistent worry about losing major attachment figures

      • Persistent worry about experiencing an event that causes separation

      • Refusal to go out

      • Reluctance about being alone

      • Nightmares involving theme of separation

      • Physical symptoms when separated from major attachment

    • Duration: At least 4 weeks4 \text{ weeks} in children/adolescents; typically 6 months6 \text{ months} in adults.

    • Treatment: CBT, Exposure Therapy, SSRI/SNRI.

  • Specific Phobia:

    • Fear of specific objects/situations (Animal, Natural environment, Blood-injection-injury, Situational).

    • Typically lasting for 6 months or more

    • Treatment: Exposure therapy and CBT are mainstays. Avoid medication unless PRN (Benzos/Hydroxyzine) for occasional triggers like flying.

  • Selective Mutism:

    • Failure to speak in specific social situations despite speaking in others.

    • Duration: at least 1 month1 \text{ month}.

    • Treatment: CBT.

Pharmacotherapy Details

  • SSRI/SNRI (First-line):

    • Usage: "Start low, go slow." Takes 4 to 6 weeks4 \text{ to } 6 \text{ weeks} for full effect. May initially worsen anxiety.

    • SSRIs: Escitalopram (LexaproLexapro) [5 to 10 mg5 \text{ to } 10\,mg initial; 10 to 20 mg10 \text{ to } 20\,mg range], Sertraline (ZoloftZoloft) [25 to 50 mg25 \text{ to } 50\,mg initial; 50 to 200 mg50 \text{ to } 200\,mg range], Fluoxetine (ProzacProzac) [10 to 20 mg10 \text{ to } 20\,mg initial].

    • SNRIs: Duloxetine (CymbaltaCymbalta) [30 to 60 mg30 \text{ to } 60\,mg range], Venlafaxine (EffexorEffexor) [75 mg75\,mg initial]. Venlafaxine can increase BP/HR at high doses.

  • Buspirone (BusparBuspar):

    • MOA: partial dopamine (D2D_2) and serotonin (5-HT1A5\text{-}HT_{1A} and 5-HT25\text{-}HT_2) agonist/antagonist.

    • Benefit: Not addictive; no dependence. Takes 2 to 4 weeks2 \text{ to } 4 \text{ weeks} for efficacy.

  • Hydroxyzine (Vistaril/AtaraxVistaril/Atarax):

    • MOA: H1H_1 histamine receptor antagonist. Produces sedation and reduced physiological arousal.

    • Use: Good for history of substance abuse. PRN for episodic/sleep anxiety.

  • Propranolol (InderalInderal):

    • MOA: Non-selective beta-11 and beta-22 adrenergic receptor antagonist.

    • Use: Reduces somatic symptoms; performance anxiety (10 or 20 mg10 \text{ or } 20\,mg given 30 to 60 minutes30 \text{ to } 60 \text{ minutes} prior).

  • Gabapentinoids:

    • Gabapentin (NeurontinNeurontin) and Pregabalin (LyricaLyrica): Blocks voltage-dependent CaCa channels. Pregabalin is a Schedule VV controlled substance.

  • Benzodiazepines:

    • MOA: Allosterically bind to GABAAGABA_A receptors, increasing GABA affinity and chloride entry, leading to hyperpolarization.

    • Risks: High addiction potential; dependence can start in 5 days5 \text{ days}. Black Box Warning (BBW) for use with opioids due to respiratory distress.

    • Examples: Alprazolam (XanaxXanax) [Intermediate], Lorazepam (AtivanAtivan) [Intermediate], Diazepam (ValiumValium) [Long-acting].


Typical Treatment Order (Anxiety or Depression)

  1. Start with SSRI (Titrate Dose)

  2. If Failed —> Consider 2nd SSRI or SNRI

  3. If some response then consider adjunct medications (Buspirone (Anxiety) or Bupropion (Depression))

  4. PRN medications for breakthrough anxiety (Hydroxyzine, Propranolol, Benzo)

  5. Therapy (CBT) should ALWAYS be offered

  6. Consider comorbid diagnosis